Imaging AI company Imbio has partnered with the Roche Group’s Genentech business to develop quantitative imaging diagnostics for lung diseases.
The multi-year agreement, announced yesterday, leverages Minneapolis-based Imbio’s expertise to build and deploy medical imaging AI technology for use in research, clinical trials and clinical practice.
“We are excited to partner with Genentech and we look forward to bringing unique solutions to the field of pulmonary imaging together,” Imbio CEO David Hannes said in a news release. “This collaboration is a great example of Imbio’s strategy to meet the growing interest by medical device and pharmaceutical companies in using imaging biomarkers and imaging AI to facilitate diagnosis of respiratory diseases.”
Dr. James Sabry, global head of Roche Pharma Partnering, noted that imaging biomarkers have the potential to significantly improve patient diagnosis, selection and understanding of response to therapy. “This collaboration, which combines Imbio’s expertise in imaging biomarkers with Genentech’s pulmonary disease expertise, has the potential to enhance drug development and deliver more personalized healthcare.”
